Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 5—May 2023
Research Letter

Burkholderia pseudomallei Laboratory Exposure, Arizona, USA

Lisa J. SpeiserComments to Author , Erin H. Graf, Maria Teresa Seville, Kai Singbartl, Mary L. Dalton, Denise Harrington, Melissa Kretschmer, Marina Kuljanin, Karen Zabel, Rebecca Sunenshine, Irene Ruberto, Heather Venkat, and Thomas E. Grys
Author affiliations: Mayo Clinic Hospital, Phoenix, Arizona, USA (L.J. Speiser, E.H. Graf, M.T. Seville, K. Singbartl, M.L. Dalton, D. Harrington, T.E. Grys); Maricopa County Department of Public Health, Phoenix (M. Kretschmer, M. Kuljanin, K. Zabel, R. Sunenshine); Arizona Department of Health Services, Phoenix (I. Ruberto, H. Venkat); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (H. Venkat)

Cite This Article


We describe an incidental Burkholderia pseudomallei laboratory exposure in Arizona, USA. Because melioidosis cases are increasing in the United States and B. pseudomallei reservoirs have been discovered in the Gulf Coast Region, US laboratory staff could be at increased risk for B. pseudomallei exposure.

Burkholderia pseudomallei bacterium, the causative agent of melioidosis, is endemic to Australia and Thailand. However, the US Centers for Disease Control and Prevention (CDC) recently discovered positive environmental samples in the Gulf Coast Region of Mississippi, USA, when investigating 2 melioidosis cases (1). In 2021, 4 melioidosis cases in the United States were found to be caused by imported aromatherapy spray contaminated with B. pseudomallei (2). Because melioidosis cases are increasing in the United States, laboratory staff potentially are at risk for B. pseudomallei exposure. In nonendemic areas, laboratory staff are unfamiliar with B. pseudomallei, and the bacterium commonly is misidentified. As occurred with the 2 melioidosis cases related to aromatherapy products (2), matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) libraries often misidentify B. pseudomallei as B. thailandensis. We describe an incidental B. pseudomallei laboratory exposure in Arizona, USA.

In mid-January 2021, the microbiology laboratory at Mayo Clinic Arizona (Phoenix, AZ, USA) identified Burkholderia species growing from an intraoperative periaortic swab sample obtained from a 58-year-old man with a mycotic aneurysm (3). Results of routine Gram stains of all specimens were negative. Aerobic cultures revealed pinpoint growth on sheep blood and chocolate agars, but not on MacConkey agar, after 18 hours. Staff performed Gram stain of the colonies, which revealed gram-negative rods. The technologist suspected an atypical Pseudomonas species and, on an open benchtop, performed oxidase testing, with positive results, and spot indole testing, with negative results. MALDI-TOF mass spectrometry provided an unvalidated B. thailandensis identification. Because of concerns that the unvalidated result could suggested B. pseudomallei, staff performed slide catalase testing on a fresh subculture per the Laboratory Response Network Sentinel Level Clinical Laboratory Protocol (4). The catalase reaction was negative, which was inconsistent with Burkholderia species. The laboratory then sent the isolate to the Mayo Clinic reference laboratory (Rochester, MN, USA) for definitive identification. By using a laboratory-developed MALDI-TOF database that was considered unvalidated, the reference laboratory presumptively identified the isolate as B. pseudomallei. The Minnesota Public Health Laboratory confirmed B. pseudomallei through molecular and biochemical methods. Repeat catalase testing found the isolate to be slide catalase–negative but weakly tube catalase–positive. The isolate was transferred to CDC for antimicrobial-susceptibility testing, which demonstrated a typical susceptibility profile to trimethoprim/sulfamethoxazole, doxycycline, amoxicillin/clavulanic acid, and ceftazidime. B. pseudomallei growth was eventually observed on both MacConkey and colistin nalidixic acid agars and on all anaerobic, mycobacterial, and fungal culture media. B. pseudomallei is a Select Agent, thus, the Federal Select Agent Program was notified, and all cultures were destroyed within 7 days of definitive identification.

Because of initial lack of clinical suspicion for B. pseudomallei, we evaluated clinical staff for exposure. We identified 30 employees who had possible exposure. We assessed each employee for exposure risk, as previously described (5), and identified 3 employees who were exposed in the microbiology laboratory: 1 high-risk and 2 low-risk exposures. The employee with high-risk exposure had a predisposing condition and performed an aerosolizing procedure outside of the biologic safety cabinet by subjecting the specimen to MALDI-TOF mass spectrometry without first inactivating it. The 2 employees with low-risk exposures participated in close inspection of the open plate growing B. pseudomallei outside of the biologic safety cabinet.

Laboratory-acquired melioidosis is extremely rare. Reports of 2 prior laboratory-acquired melioidosis cases in the United States have been published (6,7), but none have been reported since 1981. As for the high-risk exposure we describe, both published cases were attributed to aerosol exposure (6,7). B. mallei is considered to have greater potential for laboratory infection than B. pseudomallei (8).

In animal models, postexposure prophylaxis (PEP) has been shown to effectively prevent acute melioidosis if administered within 24 hours of exposure (9). However, PEP fails to prevent latent or persistent infection (10); nonetheless, consensus recommendations are to offer PEP to all employees with high- and low-risk incidents, regardless of their predisposing risk for melioidosis (5). After explaining risks versus benefits, we offered the employee with high-risk exposure a 3-week duration of trimethoprim/sulfamethoxazole PEP (5,9). However, the employee stopped PEP after 1 week because of insomnia; no subsequent PEP was prescribed because the employee stopped PEP without consulting a medical provider. On the basis of guidance from the Maricopa County Department of Public Health, we offered PEP to the employees with low-risk exposures; 1 elected to take doxycycline, and the other declined PEP.

We instructed exposed employees to monitor their temperatures 2 times a day for 21 days and notify the hospital’s occupational health department if symptoms occurred. None of the employees reported symptoms during the monitoring period.

Because B. pseudomallei can persist intracellularly for extended periods before causing clinical disease, we requested assistance from the Arizona Department of Health Services, Maricopa County Department of Public Health, and CDC to offer serologic monitoring to the exposed employees; 2 elected to undergo serologic monitoring. After 6 weeks, neither employee seroconverted.

In conclusion, lack of clinical and laboratory suspicion for B. pseudomallei resulted in incidental laboratory exposure of 3 employees. US laboratories should remain vigilant for and aware of the growth characteristics associated with B. pseudomallei to help avoid occupational exposure.

Dr. Speiser is an assistant professor of medicine at the Mayo Clinic College of Medicine, Phoenix, Arizona, USA, and serves as a senior associate consultant in the Department of Infectious Diseases and medical director of Infection Prevention and Control at the Mayo Clinic, Phoenix. Her research interests include hospital-acquired infections and emerging infectious diseases.



  1. Centers for Disease Control and Prevention. Bacteria that causes rare disease melioidosis discovered in U.S. environmental samples [cited 2022 Sep 21].
  2. Gee  JE, Bower  WA, Kunkel  A, Petras  J, Gettings  J, Bye  M, et al. Multistate outbreak of melioidosis associated with imported aromatherapy spray. N Engl J Med. 2022;386:8618. DOIPubMedGoogle Scholar
  3. Speiser  LS, Kasule  S, Hall  CM, Sahl  JW, Wagner  DM, Saling  C, et al. A case of Burkholderia pseudomallei mycotic aneurysm linked to exposure in the Caribbean via whole-genome sequencing. Open Forum Infect Dis. 2022;9:ofac136.
  4. American Society for Microbiology. Sentinel level clinical laboratory guidelines for suspected agents of bioterrorism and emerging infectious diseases; Burkholderia mallei and Burkholderia pseudomallei [cited 2021 Sep 29].
  5. Peacock  SJ, Schweizer  HP, Dance  DA, Smith  TL, Gee  JE, Wuthiekanun  V, et al. Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei. Emerg Infect Dis. 2008;14:e2. DOIPubMedGoogle Scholar
  6. Green  RN, Tuffnell  PG. Laboratory acquired melioidosis. Am J Med. 1968;44:599605. DOIPubMedGoogle Scholar
  7. Schlech  WF III, Turchik  JB, Westlake  RE Jr, Klein  GC, Band  JD, Weaver  RE. Laboratory-acquired infection with Pseudomonas pseudomallei (melioidosis). N Engl J Med. 1981;305:11335. DOIPubMedGoogle Scholar
  8. Srinivasan  A, Kraus  CN, DeShazer  D, Becker  PM, Dick  JD, Spacek  L, et al. Glanders in a military research microbiologist. N Engl J Med. 2001;345:2568. DOIPubMedGoogle Scholar
  9. Sivalingam  SP, Sim  SH, Jasper  LC, Wang  D, Liu  Y, Ooi  EE. Pre- and post-exposure prophylaxis of experimental Burkholderia pseudomallei infection with doxycycline, amoxicillin/clavulanic acid and co-trimoxazole. J Antimicrob Chemother. 2008;61:6748. DOIPubMedGoogle Scholar
  10. Barnes  KB, Steward  J, Thwaite  JE, Lever  MS, Davies  CH, Armstrong  SJ, et al. Trimethoprim/sulfamethoxazole (co-trimoxazole) prophylaxis is effective against acute murine inhalational melioidosis and glanders. Int J Antimicrob Agents. 2013;41:5527. DOIPubMedGoogle Scholar


Cite This Article

DOI: 10.3201/eid2905.221865

Original Publication Date: April 14, 2023

Table of Contents – Volume 29, Number 5—May 2023

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.



Please use the form below to submit correspondence to the authors or contact them at the following address:

Lisa Speiser, Infectious Diseases Department, Mayo Clinic, 5777 East Mayo Blvd, Phoenix, AZ 85054, USA

Send To

10000 character(s) remaining.


Page created: March 02, 2023
Page updated: April 19, 2023
Page reviewed: April 19, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.